Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more
Amoy Diagnostics Co Ltd (300685) - Net Assets
Latest net assets as of September 2025: CN¥1.97 Billion CNY
Based on the latest financial reports, Amoy Diagnostics Co Ltd (300685) has net assets worth CN¥1.97 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.25 Billion) and total liabilities (CN¥272.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.97 Billion |
| % of Total Assets | 87.86% |
| Annual Growth Rate | 47.59% |
| 5-Year Change | 63.34% |
| 10-Year Change | 643.54% |
| Growth Volatility | 58.53 |
Amoy Diagnostics Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Amoy Diagnostics Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amoy Diagnostics Co Ltd (2012–2024)
The table below shows the annual net assets of Amoy Diagnostics Co Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.84 Billion | +8.22% |
| 2023-12-31 | CN¥1.70 Billion | +13.58% |
| 2022-12-31 | CN¥1.50 Billion | +9.50% |
| 2021-12-31 | CN¥1.37 Billion | +21.37% |
| 2020-12-31 | CN¥1.13 Billion | +25.10% |
| 2019-12-31 | CN¥902.11 Million | +19.21% |
| 2018-12-31 | CN¥756.74 Million | +16.56% |
| 2017-12-31 | CN¥649.20 Million | +110.84% |
| 2016-12-31 | CN¥307.91 Million | +24.20% |
| 2015-12-31 | CN¥247.90 Million | +183.20% |
| 2014-12-31 | CN¥87.54 Million | +122.74% |
| 2013-12-31 | CN¥39.30 Million | +127.82% |
| 2012-12-31 | CN¥17.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amoy Diagnostics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 118364496730.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.18 Billion | 64.08% |
| Common Stock | CN¥398.44 Million | 21.62% |
| Other Comprehensive Income | CN¥2.14 Million | 0.12% |
| Other Components | CN¥261.48 Million | 14.19% |
| Total Equity | CN¥1.84 Billion | 100.00% |
Amoy Diagnostics Co Ltd Competitors by Market Cap
The table below lists competitors of Amoy Diagnostics Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Konka Group Co Ltd
SHE:000016
|
$834.83 Million |
|
DANAOS CORP. DL -01
F:DVW1
|
$835.08 Million |
|
CCL Products (India) Limited
NSE:CCL
|
$835.14 Million |
|
Ameresco Inc
NYSE:AMRC
|
$835.22 Million |
|
Nava Bharat Ventures Limited
NSE:NAVA
|
$834.67 Million |
|
Nanjing Sunlord Electronics Corporation LTD
SHE:300975
|
$834.47 Million |
|
Syngene International Limited
NSE:SYNGENE
|
$834.43 Million |
|
SPAREBANK 1 SOROST-NORGE
F:EZ4
|
$834.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amoy Diagnostics Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,703,320,906 to 1,843,264,757, a change of 139,943,851 (8.2%).
- Net income of 254,863,452 contributed positively to equity growth.
- Dividend payments of 60,592,428 reduced retained earnings.
- Share repurchases of 86,079,994 reduced equity.
- Other comprehensive income decreased equity by 204,431.
- Other factors increased equity by 31,957,252.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥254.86 Million | +13.83% |
| Dividends Paid | CN¥60.59 Million | -3.29% |
| Share Repurchases | CN¥86.08 Million | -4.67% |
| Other Comprehensive Income | CN¥-204.43K | -0.01% |
| Other Changes | CN¥31.96 Million | +1.73% |
| Total Change | CN¥- | 8.22% |
Book Value vs Market Value Analysis
This analysis compares Amoy Diagnostics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 378.98x to 4.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.06 | CN¥21.93 | x |
| 2013-12-31 | CN¥0.13 | CN¥21.93 | x |
| 2014-12-31 | CN¥0.29 | CN¥21.93 | x |
| 2015-12-31 | CN¥0.82 | CN¥21.93 | x |
| 2016-12-31 | CN¥1.06 | CN¥21.93 | x |
| 2017-12-31 | CN¥1.94 | CN¥21.93 | x |
| 2018-12-31 | CN¥1.95 | CN¥21.93 | x |
| 2019-12-31 | CN¥3.48 | CN¥21.93 | x |
| 2020-12-31 | CN¥2.82 | CN¥21.93 | x |
| 2021-12-31 | CN¥3.42 | CN¥21.93 | x |
| 2022-12-31 | CN¥3.81 | CN¥21.93 | x |
| 2023-12-31 | CN¥4.30 | CN¥21.93 | x |
| 2024-12-31 | CN¥4.63 | CN¥21.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amoy Diagnostics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.83%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.98%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.12x
- Recent ROE (13.83%) is below the historical average (21.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 46.22% | 20.90% | 0.57x | 3.88x | CN¥6.25 Million |
| 2013 | 56.11% | 29.65% | 0.67x | 2.81x | CN¥18.12 Million |
| 2014 | 21.86% | 17.92% | 0.61x | 2.02x | CN¥10.39 Million |
| 2015 | 8.75% | 11.92% | 0.58x | 1.26x | CN¥-3.00 Million |
| 2016 | 21.77% | 26.50% | 0.72x | 1.15x | CN¥36.24 Million |
| 2017 | 14.49% | 28.47% | 0.48x | 1.07x | CN¥29.15 Million |
| 2018 | 16.75% | 28.87% | 0.54x | 1.08x | CN¥51.06 Million |
| 2019 | 15.02% | 23.42% | 0.55x | 1.16x | CN¥45.26 Million |
| 2020 | 15.98% | 24.76% | 0.56x | 1.15x | CN¥67.48 Million |
| 2021 | 17.56% | 26.12% | 0.60x | 1.11x | CN¥103.12 Million |
| 2022 | 17.59% | 31.32% | 0.51x | 1.10x | CN¥113.77 Million |
| 2023 | 15.35% | 25.06% | 0.54x | 1.14x | CN¥91.15 Million |
| 2024 | 13.83% | 22.98% | 0.54x | 1.12x | CN¥70.54 Million |
Industry Comparison
This section compares Amoy Diagnostics Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $3,040,329,631
- Average return on equity (ROE) among peers: 4.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amoy Diagnostics Co Ltd (300685) | CN¥1.97 Billion | 46.22% | 0.14x | $834.75 Million |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |